The Problem
The Problem
Millions of people worldwide struggle with debilitating inflammatory diseases. Existing biologic treatments often come with significant side effects and can be incredibly costly, limiting access for many patients.
Millions of people worldwide struggle with debilitating inflammatory diseases. Existing biologic treatments often come with significant side effects and can be incredibly costly, limiting access for many patients.
Bridging the Gap: Addressing the Challenges of Inflammatory Disease Treatment
Bridging the Gap: Addressing the Challenges of Inflammatory Disease Treatment
The Solution
Radix BioScience is pioneering a new approach to drug development. Unlike traditional single-molecule drugs, our polymolecular formulations target multiple mechanisms involved in complex diseases. Inspired by nature's wisdom, our polymolecular drugs offer a safer, more comprehensive solution to chronic conditions by addressing both symptoms and underlying causes.
Bridging the Gap: Addressing the Challenges of Inflammatory Disease Treatment
Learn More
Gregory A Gould
Chief Executive Officer
& Chief Financial Officer
Dr. Stephen Morrissey,
OMD
Founder & Chief scientific officer
Staci J Eisner
Chief Operating officer
Dr. Freddie Ann Hoffman,
MD
Chief technical officer
Our Team
Dr. Stephen Morrissey, OMD
Dr. Freddie Ann Hoffman, MD
Dr. Steve R Kishter, MD, DDS
Dr. Steve R Kishter, MD, DDS
Chief Medical officer
Chief Medical officer
Gregory A Gould
Gregory A. Gould is the CEO, CFO and a Board Member of our company. With over 25 years of experience in the life sciences industry, Mr. Gould has held leadership roles in both publicly traded and privately held companies, including SeraCare Life Sciences, Atrix Laboratories, NewAge, Charlotte’s Web, Evolve Biologics, Colorado MEDtech, and Nanos Health. He has a proven track record of creating shareholder value through strategic management of mergers and acquisitions, restructurings, and financing activities, having led organizations through over $500 million in equity and debt financings, more than ten acquisitions, and the successful uplisting of three companies to NASDAQ. Mr. Gould is also recognized for his expertise in scaling businesses, achieving significant revenue growth, and building high-performing teams. He holds a Bachelor of Science in Business Administration with a focus on Finance and Accounting from the University of Colorado at Boulder and began his career at Arthur Andersen as a CPA.
Chief Executive Officer
& Chief Financial Officer
Chief Executive Officer & Chief Financial Officer
Dr. Stephen Morrissey, OMD
Dr. Stephen Morrissey, OMD
Founder &
Chief scientific officer
Dr. Stephen Morrissey is the Chief Science Officer and a Board Member of our company. With 40 years of clinical experience, Dr. Morrissey has specialized in botanical medicine, homeopathy, electrodiagnostic systems, and the role of nutrition in health and disease. He has spent decades developing and fine tuning a process that optimizes the selection of plant-based medicines to target specific disease conditions. He has organized 10 randomized, placebo controlled research studies to validate his innovative product development approach, all ten of which showed statistically significant health benefits for the targeted condition. He is a serial entrepreneur who has founded several companies, including the Five Element Herb Company, Plantiva, and Cortex Scientific. Through two joint venture companies he established in China, he has been instrumental in implementing improved standardization, quality, and safety of botanical medicines. Dr. Morrissey has been a leader in the production of botanical extracts, overseeing the sourcing and manufacture of over 200 tons of concentrated plant-based extracts, and has collaborated with universities to develop more than 40 health products. Dr. Morrissey earned his Bachelor of Science in Business from the University of Denver and a Doctorate in Oriental Medicine from the California Acupuncture College.
Founder & Chief scientific officer
Staci J Eisner
Staci J Eisner
Chief Operating officer
Ms. Staci J. Eisner serves as the Chief Operating Officer of Radix Bioscience. Ms. Eisner graduated with honors in both chemistry and biochemistry of natural products from Cornell University. In her role as COO, Ms. Eisner manages the company’s processes, supply chain, and overall compliance. With extensive experience as Director of Quality Assurance and Regulatory Affairs at U.S., Japanese, and Swiss dose form and extract manufacturers, Ms. Eisner has been instrumental in developing product methods and validation programs. Her expertise extends to her involvement with industry organizations such as the Institute for Nutraceutical Advancement, where she contributed to the Methods Validation Program, the Board of Trustees of the American Herbal Products Association (AHPA), and the NSF/ANSI Joint Task Force on Dietary Supplements. As a Board member of the American Herbal Pharmacopeia, she has also managed the creation of three technical documents for AHPA, focusing on industry-wide quality assurance issues related to manufacturing, marker compounds, and botanical standardization. Ms. Eisner’s leadership and strategic vision ensure the seamless operation of Radix Bioscience, aligning operational excellence with the company’s mission to revolutionize healthcare through innovative therapies.
Dr. Freddie Ann Hoffman, MD
Dr. Freddie Ann Hoffman, MD
Chief technical officer
Dr. Freddie Ann Hoffman serves as the Chief Technical Medical Officer of our company. She is also the CEO of HeteroGeneity, LLC, a scientific and regulatory consulting firm she founded in 2003. Dr. Hoffman has an extensive background in both the public and private sectors, including her role as Chief of the Cytokines, Growth Factors, and Oncologic Products Branch at the FDA Center for Biologics Evaluation and Research (CBER). She led a team that played a crucial role in the licensing of 15 biologic drugs during her time at the FDA. She also served in the Office of the FDA Commissioner as the Deputy Director of the Medicine Branch, where she chaired the Agency’s Working Group on Botanical Drugs, producing the Agency’s guidance on botanical drug development. Dr. Hoffman received a Bachelor of Science in Chemistry at UCLA, a Doctorate of Medicine and residency at UC Davis, and completed a fellowship in pediatric hematology-oncology at the National Cancer Institute, where she conducted significant clinical and laboratory research. Following retirement from the US Public Health Service as a Captain, she served as the Senior Director for New Technology and Product Development at Pfizer-Warner Lambert Consumer Health Care. Her company, HeteroGeneity, assisted sponsors in achieving the first two FDA New Drug Approvals for prescription botanical drugs in the United States.
Dr. Steve R Kishter, MD, DDS
Dr. Steve R Kishter, MD, DDS
Chief medical officer
Dr. Steven Kishter is our Chief Medical Officer. He is also CEO of The Avenue 16 Group LLC, a business development consultancy with a focus on naturally complex drugs. He holds an undergraduate degree in Neuroscience from McGill University and began a research career in the NCI Laboratory of Tumor Biology, led by Robert A Gallo, MD and then later in the NCI Pediatric Oncology Branch. His clinical training includes a doctorate of dental surgery from the U of Maryland and medical degree from Albany School of Medicine. During a fellowship in the NCI Surgical Oncology Branch, he worked both clinically and in the lab. His broad clinical and drug development experience includes the design, implementation, and analyses of clinical study protocols for drugs and biologics under IND, as well as the surgical procedures and care of patients with cancer, AIDs, and other conditions treated at the National Institutes of Health Clinical Center. Returning to the U of Maryland, Dr. Kishter trained and received board certification in oral-maxillofacial surgery. Moving to the private sector, he became the Medical Director for the Advil® franchise at Wyeth Consumer Healthcare, where he also served on the company’s New Technology Search Team before returning to the DC area to practice oral-max surgery, which he continues to do part-time, as he remains involved in new product development as a Medical-Clinical expert.
